Efficacy analyses of a randomized phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advanced or recurrent gastric cancer refractory to prior S-1 chemotherapy.
Abstract:69 Background: There has been no established regimen as the second-line treatment for advanced gastric cancer (AGC), though CPT-11 showed survival benefit over BSC. Combination of CPT-11 with CDDP is one of the promising regimens as the second-line chemotherapy after S-1 mono-therapy. Methods: This is a prospective, multicenter randomized phase III study comparing CPT-11+CDDP (Arm A) vs. CPT-11 alone (Arm B) in patients with advanced or recurrent gastric cancer resistant to S-1 mono-therapy or prior adjuvant … Show more
“…Notably, the proportion of patients receiving third-line therapy was the same (75%) in both groups. The results of another randomized trial (ECRIN) have been reported in the abstract form [18], in which irinotecan plus cisplatin (n=84) was compared with irinotecan alone (n=84) in patients refractory to an S-1 containing regimen. WJOG 4007 [19] is a RCT comparing weekly paclitaxel (n=108) with biweekly irinotecan (n=111) in GC patients refractory to fluoropyrimidines plus cisplatin.…”
Section: Seeking the Best Regimen Of Second-line Therapymentioning
confidence: 99%
“…The agents investigated by these trials include chemotherapeutic drugs [17][18][19][20], a molecular targeting agent [21], and their combinations [22][23][24][25][26].…”
Section: Seeking the Best Regimen Of Second-line Therapymentioning
“…Notably, the proportion of patients receiving third-line therapy was the same (75%) in both groups. The results of another randomized trial (ECRIN) have been reported in the abstract form [18], in which irinotecan plus cisplatin (n=84) was compared with irinotecan alone (n=84) in patients refractory to an S-1 containing regimen. WJOG 4007 [19] is a RCT comparing weekly paclitaxel (n=108) with biweekly irinotecan (n=111) in GC patients refractory to fluoropyrimidines plus cisplatin.…”
Section: Seeking the Best Regimen Of Second-line Therapymentioning
confidence: 99%
“…The agents investigated by these trials include chemotherapeutic drugs [17][18][19][20], a molecular targeting agent [21], and their combinations [22][23][24][25][26].…”
Section: Seeking the Best Regimen Of Second-line Therapymentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.